Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02646917 · ClinicalTrials.gov registry record · NA
SkinPen Efficacy on Acne Scars on the Face and/or Back
A NA study of Atrophic Acne Scar, sponsored by Bellus Medical.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT02646917: Completed NA study of Atrophic Acne Scar, sponsored by Bellus Medical.
NCT02646917 is a NA study of Atrophic Acne Scar that has completed, run by Bellus Medical. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02646917, a NA study of Atrophic Acne Scar, has completed, sponsored by Bellus Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This single-center, clinical trial will take place over a 90 day course followed by 1-month and 6-month post treatment visits to assess the efficacy and tolerability of the SkinPen device when used on both men and women on the face and/or back.
Primary Outcome
Goodman and Baron's Qualitative grading system. Possible scores range from 1 = mild to 4 = severe.
Conditions Studied
Interventions
- PROCEDURE Aesthetic Microneedling Treatment
Study Locations (1)
Texas
- Stephens & Associates - Richardson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-07-25 |
| Phase | NA |
What the finished NCT02646917 record still lists
NCT02646917 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Atrophic Acne Scar appearing as the primary indexed condition, and to 1 intervention - of which Aesthetic Microneedling Treatment is the first listed.
NCT02646917 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02646917 about?
NCT02646917 is a clinical study titled "SkinPen Efficacy on Acne Scars on the Face and/or Back". This single-center, clinical trial will take place over a 90 day course followed by 1-month and 6-month post treatment visits to assess the efficacy and tolerability of the SkinPen device when used on both men and women on the face and/or back.
What is the current status of trial NCT02646917?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2015-12. Estimated completion is 2017-07-25.
What conditions does trial NCT02646917 study?
This clinical trial studies the following conditions: Atrophic Acne Scar.
What interventions are being tested in trial NCT02646917?
The interventions under investigation include: Aesthetic Microneedling Treatment (PROCEDURE).
Who is sponsoring clinical trial NCT02646917?
This trial is sponsored by Bellus Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02646917 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02646917's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia